arrow
T

Taku Kobayashi

kitasato university kitasato institute hospital
H指数:48
被引数:9,489

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness, safety, and clinical outcomes of treatment with the oral α4-integrin antagonist carotegrast methyl in patients with active ulcerative colitis: a multicenter observational study (CANAL study)

奥法木单抗(carotegrast methyl)口服α4整合素拮抗剂治疗活动性溃疡性结肠炎的有效性、安全性和临床结局:一项多中心观察性研究(CANAL研究)

2026-09-280
OAAI
Association Between Bowel Urgency and Intestinal Ultrasound Parameters in Ulcerative Colitis: Insights Into Transmural Inflammation and Symptom Pathophysiology

溃疡性结肠炎中肠道急迫性与肠超声参数的相关性:对肠壁炎症和症状病理生理学的见解

2026-09-090
OAAI
Distinct predictive factors for acute severe ulcerative colitis in East Asian and Western populations

东亚和西方人群中急性重度溃疡性结肠炎的不同预测因素

2026-06-050
OAAI
Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL-23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease

亚太胃肠病学协会(APAGE)关于小分子和IL-23 p19抑制剂在溃疡性结肠炎和克罗恩病中应用的临床实践指南

2026-05-120
OAAI
Time to rethink washout periods in inflammatory bowel disease clinical trials: an international Delphi consensus

是时候重新思考炎症性肠病临床试验中的清洗期:一项国际德尔菲共识

2026-05-010
PRE
Mirikizumab four-year sustained and durable efficacy and safety in ulcerative colitis: Final findings from the LUCENT-3 open-label extension study

美瑞克zumab治疗溃疡性结肠炎四年的持续和持久疗效与安全性:来自LUCENT-3开放标签扩展研究的最终结果

2026-03-020
OA
Personalized infliximab rescue therapy to maximize colectomy-free survival in patients with acute severe ulcerative colitis

针对急性重症溃疡性结肠炎患者的个性化英夫利昔单抗挽救治疗以最大化结肠切除术-free生存率

2026-03-010
PRE
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by Age

奥扎尼妥(Ozanimod)在按年龄分层的中度至重度活动性溃疡性结肠炎患者中的安全性与有效性

2025-11-010
PRE
Mirikizumab Provides Sustained Long-Term Efficacy Up to 4 Years of Treatment for Ulcerative Colitis: Extended Induction Results From the LUCENT-3 Open-Label Study

Mirikizumab为溃疡性结肠炎患者提供长达4年的持续长期疗效:来自LUCENT-3开放标签研究的扩展诱导结果

2025-10-010
PRE
Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study)

优化卡托格斯特甲基在溃疡性结肠炎中的使用:患者特征分析、预测性生物标志物及疗效评估时机(ASPECT研究)

2025-09-220
OAAI
Mirikizumab impact on disease clearance in patients with moderately to severely active ulcerative colitis: analysis of a pre-specified LUCENT trial endpoint

Mirikizumab对中度至重度活动性溃疡性结肠炎患者疾病清除率的影响:对LUCENT试验预设终点的分析

2025-09-010
OAAI
Asia Pacific association of gastroenterology consensus statements on histopathological evaluation of inflammatory bowel diseases

亚太胃肠病学协会关于炎症性肠病组织病理学评估的共识声明

2025-08-190
OA
Comparative effectiveness of tofacitinib versus upadacitinib for the treatment of acute severe ulcerative colitis

托法替布与乌帕替尼治疗急性重度溃疡性结肠炎的疗效比较

2025-07-260
OAAI
Characteristic gene expression profile of intestinal mucosa early in life promotes bacterial colonization leading to healthy development of the intestinal environment

肠道黏膜早期生命中的特征性基因表达谱促进细菌定植,从而导致肠道环境的健康发育。

2025-05-260
OA
Real-World Effectiveness and Safety of Vedolizumab in Patients ≥ 70 Versus < 70 Years With Ulcerative Colitis: Multicenter Retrospective Study

溃疡性结肠炎患者中≥70岁与<70岁患者接受维多利珠单抗治疗的实际有效性与安全性:多中心回顾性研究

2025-05-150
OA
Real-World Effectiveness and Safety of Mirikizumab Induction Therapy in Patients With Ulcerative Colitis: A Multicentre Retrospective Observational Study

真实世界中溃疡性结肠炎患者接受Mirikizumab诱导治疗的有效性与安全性:一项多中心回顾性观察性研究

2025-04-092
OAAI